NASDAQ:IRWD - Ironwood Pharmaceuticals Stock Price, Price Target & More

Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.06. The biotechnology company had revenue of $69.16 million for the quarter, compared to the consensus estimate of $78.65 million. Ironwood Pharmaceuticals had a negative return on equity of 2,073.20% and a negative net margin of 34.12%. The business's revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.33) EPS. View Ironwood Pharmaceuticals' Earnings History.

Ironwood Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Ironwood Pharmaceuticals.

7 brokers have issued 12 month price targets for Ironwood Pharmaceuticals' shares. Their predictions range from $13.00 to $25.00. On average, they anticipate Ironwood Pharmaceuticals' share price to reach $19.50 in the next year. This suggests that the stock has a possible downside of 2.6%. View Analyst Ratings for Ironwood Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

Some companies that are related to Ironwood Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF), Perrigo (PRGO), Beigene (BGNE), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Valeant Pharmaceuticals (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR) and FibroGen (FGEN).

Media stories about IRWD stock have trended very positive this week, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ironwood Pharmaceuticals earned a daily sentiment score of 0.51 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 48.24 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Ironwood Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.14%), Essex Investment Management Co. LLC (0.02%), Amalgamated Bank (0.01%) and V Wealth Management LLC (0.01%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.

IRWD stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.

IRWD stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, V Wealth Management LLC and Amalgamated Bank. View Insider Buying and Selling for Ironwood Pharmaceuticals.

Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IRWD stock can currently be purchased for approximately $20.02.

Ironwood Pharmaceuticals has a market capitalization of $3.04 billion and generates $298.28 million in revenue each year. The biotechnology company earns $-116,930,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Ironwood Pharmaceuticals employs 730 workers across the globe.

Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]